ReviewBioMed research international2018
Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma.
Review in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 140 citations in OpenAlex.
- Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis.Respiratory research · 2019Pooled it
- Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Impact of Biologics on Oscillometry Defined Small Airway Dysfunction in Uncontrolled Asthma.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Review
- The Impact of BMI on the Effect of Biologic Agents for Severe Asthma.Pulmonary therapy · 2026Review
- Beyond Triple Therapy: Anti-Type 2 Biologic Therapies for Eosinophilic COPD and Respiratory Comorbidities - a Review of Clinical Evidence.Current allergy and asthma reports · 2026Review
- Comparative efficacy of mepolizumab and benralizumab in severe eosinophilic asthma: a retrospective cohort study.BMC pulmonary medicine · 2026Article
- Benralizumab in Severe Eosinophilic Asthma: Toward Disease Control and Evolving Treatment Paradigms.Journal of inflammation research · 2026Review
- Targeted Biologic Therapies in Severe Asthma: Mechanisms, Biomarkers, and Clinical Applications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Patient response and remission in respiratory disease: Special focus on severe asthma and chronic obstructive pulmonary disease.The Journal of international medical research · 2025Review
- Effect of benralizumab treatment on the airway microbiome in COPD.ERJ open research · 2025Article
- Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.International journal of molecular sciences · 2025Review
- Biologic therapies targeting type 2 cytokines are effective at improving asthma symptoms and control-a systematic review and meta-analysis.The journal of allergy and clinical immunology. Global · 2025Article
- Simultaneous treatment with benralizumab and ustekinumab in a patient with severe asthma and ulcerative colitis.Lung India : official organ of Indian Chest Society · 2025Article
- Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.The European respiratory journal · 2024Observational
- Relapsing Eosinophilia in a Severe Allergic Asthma Patient on Biological Therapy.Journal of clinical medicine · 2024Article
- Severe Asthma or Chronic Obstructive Pulmonary Disease with Eosinophilic Inflammation? From Uncertainty to Remission under Anti IL-5R Therapy.Medicina (Kaunas, Lithuania) · 2024Article
- The interleukin-4/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps.Frontiers in immunology · 2024Review
- Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies.Frontiers in immunology · 2024Review
- Personalized Medicine in Severe Asthma: From Biomarkers to Biologics.International journal of molecular sciences · 2023Review
- Factors influencing poor response to type 2 targeted therapies in severe asthma: a retrospective cohort study.BMC pulmonary medicine · 2023Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a very frequent chronic airway disease that includes many different clinical phenotypes and inflammatory patterns. In particular, eosinophilic bronchial inflammation is often associated with allergic as well as nonallergic asthma. The most important cytokine involved in the induction, maintenance, and amplification of airway eosinophilia in asthma is interleukin-5 (IL-5), released by both T helper 2 (Th2) lymphocytes and group 2 innate lymphoid cells (ILC2). Hence, IL-5 and its receptor are suitable targets for selective biologic drugs which can play a key role in add-on treatment of severe eosinophilic asthma refractory to corticosteroids. Within such a context, the anti-IL-5 monoclonal antibodies mepolizumab and reslizumab have been developed and approved for biological therapy of uncontrolled eosinophilic asthma. In this regard, on the basis of several successful randomized controlled trials, the anti-IL-5 receptor benralizumab has also recently obtained the approval from US Food and Drug Administration (FDA).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.